Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study

Ida M. Heerfordt, Magnus Middelboe, Christian Kjer Heerfordt, Henrik Horwitz, Rasmus Huan Olsen

Open source

DOI
10.1002/pds.70272
Published
2025-11
Container
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/pds.70272,
  title = {Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study},
  author = {Ida M. Heerfordt and Magnus Middelboe and Christian Kjer Heerfordt and Henrik Horwitz and Rasmus Huan Olsen},
  year = {2025},
  journal = {Pharmacoepidemiology and Drug Safety},
  doi = {10.1002/pds.70272},
  url = {https://doi.org/10.1002/pds.70272}
}

RIS

TY  - JOUR
TI  - Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study
AU  - Ida M. Heerfordt
AU  - Magnus Middelboe
AU  - Christian Kjer Heerfordt
AU  - Henrik Horwitz
AU  - Rasmus Huan Olsen
PY  - 2025
JO  - Pharmacoepidemiology and Drug Safety
DO  - 10.1002/pds.70272
UR  - https://doi.org/10.1002/pds.70272
ER  - 

APA

Heerfordt, I. M., Middelboe, M., Heerfordt, C. K., Horwitz, H., & Olsen, R. H. (2025). Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70272

Source records